CD19-CD34 CAR transduced T cell therapy (Loyola University)

N/A

Report date: 2022/12/31 17:29:52

Base Information

Drug NameCD19-CD34 CAR transduced T cell therapy (Loyola University)

Drug Alias NameCD19-CD34 CAR转导的T细胞疗法（洛约拉大学）

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesLoyola University Chicago

China Registration ClassN/A

Develop Information

Active CompaniesLoyola University

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A